Identification of CD318 (CDCP1) as novel prognostic marker in AML

In conclusion, FACS-based determination of CD318 expression may serve as novel prognostic factor depending on implemented therapy in AML patients.
Source: Annals of Hematology - Category: Hematology Source Type: research